Retrospective evaluation of chemical venous thromboembolism prophylaxis in traumatic brain injury

Background: Traumatic brain injury (TBI) is a risk factor for venous thromboembolism (VTE) but few studies address optimal timing or choice of agent. Materials and Methods: Retrospective review of moderate to severe TBI patients receiving chemical VTE prophylaxis (early initiation [≤ 72 h from admis...

Full description

Bibliographic Details
Published in:	Surgery in Practice and Science
Main Authors:	Emily K. Hollfelder, Stephen Rappaport, Julius Cheng, Jignesh H. Patel
Format:	Article
Language:	English
Published:	Elsevier 2023-06-01
Subjects:	Brain injuries Traumatic Venous thromboembolism Anticoagulants Heparin Heparin, Low-molecular-weight
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666262023000141

Similar Items

The association of timing of pharmacological prophylaxis and venous thromboembolism in patients with moderate-to-severe traumatic brain injury: A retrospective cohort study
by: Hasan M Al-Dorzi, et al.
Published: (2022-01-01)

Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
by: Stefania Cavazza, et al.
Published: (2025-10-01)

Timing and Type of Venous Thromboembolic Chemoprophylaxis Is Associated with Acute Traumatic Brain Injury Outcomes
by: Darwin Ang, et al.
Published: (2022-11-01)

Anticoagulation approach in morbid obesity: a comprehensive review on venous thromboembolism management
by: Victorita Sorodoc, et al.
Published: (2024-12-01)

Delayed prophylaxis with unfractionated heparin increases the risk of venous thromboembolic events in patients with moderate to severe traumatic brain injury: a retrospective analysis
by: Giovanna Brandi, et al.
Published: (2020-03-01)

Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism prophylaxis: a systematic review of efficacy, safety, and cost-effectiveness
by: Bin Li, et al.
Published: (2025-09-01)

Comparative effectiveness of aspirin for symptomatic venous thromboembolism prophylaxis in patients undergoing total joint arthroplasty, a cohort study
by: Verinder Sidhu, et al.
Published: (2023-08-01)

New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism
by: Wumaier K, et al.
Published: (2022-08-01)

Practical Considerations for the Management of Cancer-Associated Venous Thromboembolism: A Guide for the General Oncology Practitioner
by: Amye M. Harrigan, et al.
Published: (2022-09-01)

Venous thromboembolism in patients with heart failure
by: O. V. Averkov, et al.
Published: (2011-08-01)

Comparison of pain after prophylactic anticoagulant injections to prevent venous thromboembolism
by: Margaret Shyu, et al.
Published: (2024-08-01)

Comparative efficacy of venous thromboembolism prophylaxis in patients with blunt trauma: Direct thrombin inhibitors vs low-molecular-weight heparin
by: Jen-Fu Huang, et al.
Published: (2025-05-01)

Treatment of venous thromboembolism – effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management
by: Hass Bastian, et al.
Published: (2012-12-01)

Prevention of venous thromboembolic events in ischemic stroke
by: Vladimir Anatolyevich Parfenov
Published: (2013-11-01)

Strategies involving low-molecular-weight heparin for the treatment and prevention of venous thromboembolism in patients with obesity: A systematic review and meta-analysis
by: Junjie Liu, et al.
Published: (2023-03-01)

Thromboprophylaxis in obstetrics: who, when and how
by: A V Kulikov, et al.
Published: (2014-10-01)

Real-world practices of low-molecular-weight heparin for venous thromboembolism prophylaxis in patients hospitalized with COVID-19: a multicenter prospective study from China
by: Feiya Xu, et al.
Published: (2025-06-01)

OPTIONS FOR USE OF APPROPRIATE ANTICOAGULANT THERAPY IN PATIENTS WITH THERMAL INJURY WITH A HIGH RISK OF THROMBOEMBOLIC COMPLICATIONS DEVELOPMENT ASSOCIATED WITH RECURRENT INTESTINAL BLEEDING
by: V. S. Borisov, et al.
Published: (2016-02-01)

The safety of low-molecular-weight heparins in the prevention of venous thromboembolism in surgically-treated cancer patients: results of a multicentre observational study
by: Tomasz Olesiński, et al.
Published: (2017-06-01)

Efficacy and Safety of Edoxaban in Cancer-Associated Venous Thromboembolism: A Real World Retrospective Study
by: Elisa Grifoni, et al.
Published: (2022-04-01)

Anticoagulant Activity of Heparins from Different Animal Sources are Driven by a Synergistic Combination of Physical-chemical Factors
by: Stephan N.M.C.G. Oliveira, et al.
Published: (2022-10-01)

Efficacy and safety of direct oral anticoagulants for preventing venous thromboembolism in hospitalized cancer patients: a national multicenter retrospective cohort study
by: Shuyi Wu, et al.
Published: (2024-07-01)

Utility of the Caprini risk assessment model in guiding venous thromboembolism prophylaxis after abdominoplasty
by: Abdulaziz Asiry, et al.
Published: (2025-12-01)

Comparison of the prevalence of venous thromboembolism in patients treated with enoxaparin and heparin: A cross-sectional study in the intensive care unit of Imam Khomeini Hospital in Ahvaz
by: Mohsen Savaie, et al.
Published: (2022-05-01)

A comparison of international clinical practice guidelines for postpartum venous thromboembolism prophylaxis
by: Sarah Ephraums, et al.
Published: (2025-02-01)

PERIOPERATIVE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ROUTINE ONCOSURGERY
by: V. E. Khoronenko, et al.
Published: (2016-12-01)

Significance, aetiology and prevention of venous thromboembolism in pregnancy and puerperium
by: Kutlešić Marija, et al.
Published: (2014-01-01)

Venous thromboembolism treatment in patients with cancer: reflections on an evolving landscape
by: Agnes Y.Y. Lee
Published: (2024-02-01)

VENOUS THROMBOEMBOLIC COMPLICATIONS IN OBSTETRICS AND GYNECOLOGY
by: G. F. Totchiev, et al.
Published: (2017-12-01)

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study
by: Christoph Dibiasi, et al.
Published: (2022-04-01)

Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, or both?
by: Sergio Siragusa
Published: (2011-12-01)

Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, or both?
by: Sergio Siragusa
Published: (2011-12-01)

Prescriber perceptions of the safety and efficacy of unfractionated heparin versus low molecular weight heparin in the acute treatment phase: a qualitative study
by: Danielle Green, et al.
Published: (2024-12-01)

Pharmacoeconomic study on rivaroxaban vs conventional venous thromboembolism prophylaxis following elective total hip or knee replacement surgery in Serbia: Single centre study
by: Perović Saša R., et al.
Published: (2017-01-01)

Venous Thromboembolism Chemoprophylaxis Within 24 Hours of Surgery for Spinal Cord Injury: Is It Safe and Effective?
by: Seth Ahlquist, et al.
Published: (2020-06-01)

Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China
by: Yue Wu, et al.
Published: (2024-09-01)

Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines
by: Pierre Fontana, et al.
Published: (2020-06-01)

In-Hospital Mortality and Hemorrhagic Risks in Traumatic Brain Injury Patients with Early vs. Late Venous Thromboembolism
by: Sophie Samuel, et al.
Published: (2025-01-01)

Clinical and Pathophysiological Aspects of the Effect of Anticoagulants on Bone Tissue
by: O. D. Ostroumova, et al.
Published: (2020-07-01)

What has changed over the year in the prevention of venous thromboembolic events in pregnant women and puerperas?
by: V. O. Bitsadze, et al.
Published: (2023-09-01)